/drug-combination-safety

Not medical advice. Speak with a healthcare professional before using any medication.


Feel confident about your treatment — learn what’s safe.
Contact UsConcurrent use of estradiol and St. John's wort requires prescriber evaluation. According to Lexicomp and per DailyMed, St. John's wort (Hypericum perforatum) is a potent inducer of CYP3A4 and P-glycoprotein — metabolic pathways relevant to estradiol clearance. This interaction may reduce estradiol plasma levels and compromise the effectiveness of hormone therapy.
Per DailyMed, St. John's wort significantly induces hepatic CYP3A4 and intestinal P-glycoprotein. Estradiol — whether in oral, patch, gel, or spray formulations — is metabolized through CYP3A4-dependent pathways. When these pathways are induced, estradiol is cleared more rapidly than under normal conditions, potentially reducing systemic exposure below therapeutic levels.
According to Lexicomp, clinically relevant consequences of this interaction may include:
This interaction represents a concern for reliability of hormone therapy, not an acute toxicity risk. However, subtherapeutic estradiol levels may affect bone protection, vasomotor control, and other therapeutic goals depending on why HRT was prescribed.
If you are currently taking both and have concerns, contact your prescriber. If you are considering starting St. John's wort while on estradiol therapy, consult your prescriber first to discuss the potential impact on hormone levels and whether alternative options may be appropriate. This page does not constitute medical advice or a recommendation for any specific combination.
Compounded medications are not FDA-approved. A licensed prescriber should determine whether any compounded preparation is appropriate based on individual patient needs.
Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. FDA-approved medications should be considered first when commercially available options meet patient needs. Compounded preparations are prepared by licensed pharmacists in response to valid prescriptions for individual patients. Interaction and safety information on this page is based on FDA-approved formulations and may not fully apply to compounded preparations, which differ in formulation and regulatory status.
Common
Moderate
According to Lexicomp, St. John's wort induces CYP3A4 and P-glycoprotein, which may increase estradiol clearance and reduce systemic estradiol exposure. This may result in return of vasomotor symptoms such as hot flashes or night sweats, or reduced effectiveness of HRT for other therapeutic indications. Consult a clinician if symptoms that were previously controlled by hormone therapy re-emerge.
Normally lasts for:
2–6 hours
Occasional
Mild
Per DailyMed, reduced estradiol levels associated with CYP3A4 induction may result in unexpected spotting or breakthrough bleeding, particularly in patients on combined HRT regimens or in those whose regimen was titrated to a lower estradiol dose. Consult a clinician if breakthrough bleeding occurs, as it may indicate subtherapeutic estradiol levels requiring prescriber evaluation.
Normally lasts for:
4–12 hours
Occasional
Moderate
Per FDA-approved labeling, estradiol supports mood regulation in estrogen-sensitive brain regions. A reduction in estradiol levels due to CYP3A4 induction by St. John's wort may contribute to return of irritability, anxiety, or low mood, even as St. John's wort itself is used for mood-related indications. Consult a clinician if mood symptoms return or worsen during concurrent use.
Normally lasts for:
1–8 hours
Common
Mild
Per FDA-approved labeling, headache is a reported adverse effect of estradiol. Fluctuations in estradiol levels associated with enzyme induction may contribute to headaches in some patients. Per DailyMed, St. John's wort has also been associated with headache as an adverse effect. Consult a clinician if headaches are persistent, severe, or new in onset during concurrent use.
Normally lasts for:
2–6 hours
Occasional
Mild
Per FDA-approved labeling, breast tenderness and fullness are reported adverse effects of estradiol. Fluctuations in estradiol plasma levels during concurrent St. John's wort use may affect the pattern or severity of these symptoms. Consult a clinician if breast symptoms are new, persistent, or associated with other changes.
Normally lasts for:
6–24 hours
Common
Mild
Per DailyMed, nausea, bloating, and gastrointestinal discomfort have been reported as adverse effects of St. John's wort. Estradiol may also cause mild gastrointestinal symptoms in some patients. Consult a clinician if gastrointestinal symptoms are persistent, severe, or affect medication adherence.
Important labeled warning: Per FDA-approved labeling, estradiol carries a boxed warning for increased risks of endometrial cancer, cardiovascular disorders (stroke, DVT, PE), and probable dementia in certain populations. These risks should be weighed against benefits by a licensed prescriber. Consult a clinician if you have concerns about these risks.
Normally lasts for:
1–4 hours
Need Help Taking This the Right Way?
Quick, caring advice from pharmacists who know these medications inside out.

This page provides educational information only and is not a substitute for professional medical advice. If you have taken estradiol while using St. John's wort and have concerns, contact your prescriber or pharmacist for guidance specific to your clinical situation.
Steps to take:
Symptoms that warrant clinician contact:
Seek emergency care if you experience:
Contact your prescriber or pharmacist with any questions about managing this interaction.
Let’s talk — we focus on your unique needs, with support you can trust.
Per FDA-approved labeling, estradiol is a naturally occurring estrogen used in hormone therapy to address symptoms of estrogen deficiency, including vasomotor symptoms, sleep disturbances, genitourinary changes, and mood changes related to hormonal fluctuation. It acts on estrogen receptors throughout the body to support hormone-sensitive tissues and physiological processes.
According to Lexicomp, the clinical relevance of estradiol in the context of St. John's wort use lies in its susceptibility to CYP3A4-mediated clearance. St. John's wort is a recognized inducer of this pathway, which can accelerate estradiol metabolism and reduce systemic exposure. A prescriber should assess whether hormone therapy goals can be reliably achieved when St. John's wort is co-administered, and whether alternative options are warranted.
St. John's wort (Hypericum perforatum) is an herbal supplement used for mood-related indications. Per DailyMed, it is a potent inducer of CYP3A4 and P-glycoprotein — hepatic and intestinal pathways responsible for metabolizing a broad range of medications, including hormones such as estradiol.
According to Lexicomp, this enzyme induction is clinically significant for medications that depend on CYP3A4 for their clearance. In the context of estradiol use, St. John's wort can accelerate estradiol metabolism, potentially resulting in subtherapeutic estradiol plasma levels. This may compromise the effectiveness of hormone therapy without any acute toxic event. A prescriber should be consulted before combining St. John's wort with any hormone therapy regimen.
Talk with us — we’ll walk through your unique situation and support you in feeling confident about your hormone journey.
Does St. John’s wort lower estradiol levels?
According to Lexicomp, St. John's wort is a potent inducer of CYP3A4 and can accelerate the hepatic metabolism of oral estradiol, potentially resulting in reduced plasma estradiol levels. This may manifest as diminished vasomotor symptom control or reduced effectiveness of HRT for other therapeutic indications. Oral estradiol undergoes significant first-pass hepatic metabolism, making it more susceptible to this interaction.
Per DailyMed, transdermal estradiol (patch, gel, spray) bypasses first-pass hepatic metabolism and may be less susceptible to this interaction, though systemic CYP3A4 induction may still have some effect. If new or returning symptoms emerge during concurrent use, contact a prescriber for evaluation. Dose adjustment or alternative formulations may be considered by the prescriber based on clinical response.
Does St. John’s wort affect estradiol hormone therapy?
According to Lexicomp, St. John's wort may increase the hepatic clearance of estradiol by inducing CYP3A4, potentially resulting in reduced systemic estradiol exposure. The primary clinical concern is reduced hormone therapy effectiveness rather than acute drug toxicity. The degree of effect may vary with formulation: oral estradiol is more susceptible than transdermal forms due to first-pass metabolism.
If symptoms that were previously controlled by HRT — such as hot flashes, sleep disturbances, or mood changes — re-emerge during concurrent use of St. John's wort, contact your prescriber. Do not adjust estradiol doses or discontinue St. John's wort without prescriber direction, as abrupt changes may also affect clinical stability.
Does St. John’s wort reduce estradiol effectiveness?
According to Lexicomp, St. John's wort may reduce estradiol plasma levels by inducing hepatic CYP3A4, which accelerates estradiol clearance. This does not represent acute estradiol toxicity; rather, the concern is subtherapeutic estradiol levels and diminished HRT effectiveness. The interaction does not make estradiol acutely unsafe, but may impair its therapeutic benefits.
If estradiol therapy was prescribed for specific indications such as vasomotor control, mood stabilization, or bone protection, subtherapeutic levels may compromise these goals. Contact a prescriber if any of the following occur during concurrent use:
Prescriber assessment is needed to determine whether a dose adjustment or alternative approach is appropriate.
Does St. John’s wort interfere with estradiol patches?
According to Lexicomp, St. John's wort may reduce plasma levels of estradiol through CYP3A4 induction. Per DailyMed, transdermal estradiol (patch, gel, spray) undergoes less first-pass hepatic metabolism than oral forms, and the magnitude of this interaction may be smaller — though not necessarily absent — with transdermal administration.
A prescriber should evaluate whether continued concurrent use is appropriate and whether any modifications to the HRT regimen are warranted.
Ask your prescriber whether a compounded option is appropriate for you. Contact Voshell's Pharmacy for customized compounding support.